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Abstract
Cancer aggressiveness may result from the selective pressure of a harsh nutrient-deprived 
microenvironment. Here we illustrate how such conditions promote chemotherapy resistance in 
pancreatic ductal adenocarcinoma (PDAC). Glucose or glutamine withdrawal resulted in a 5- to 
10-fold protective effect with chemotherapy treatment. PDAC xenografts were less sensitive to 
gemcitabine in hypoglycemic mice compared with hyperglycemic mice. Consistent with this 
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observation, patients receiving adjuvant gemcitabine (n = 107) with elevated serum glucose levels 
(HgbA1C > 6.5%) exhibited improved survival. We identified enhanced antioxidant defense as a 
driver of chemoresistance in this setting. ROS levels were doubled in vitro by either nutrient 
withdrawal or gemcitabine treatment, but depriving PDAC cells of nutrients before gemcitabine 
treatment attenuated this effect. Mechanistic investigations based on RNAi or CRISPR approaches 
implicated the RNA binding protein HuR in preserving survival under nutrient withdrawal, with or 
without gemcitabine. Notably, RNA deep sequencing and functional analyses in HuR-deficient 
PDAC cell lines identified isocitrate dehydrogenase 1 (IDH1) as the sole antioxidant enzyme 
under HuR regulation. HuR-deficient PDAC cells lacked the ability to engraft successfully in 
immunocompromised mice, but IDH1 overexpression in these cells was sufficient to fully restore 
chemoresistance under low nutrient conditions. Overall, our findings highlight the HuR–IDH1 
regulatory axis as a critical, actionable therapeutic target in pancreatic cancer.
Introduction
Low nutrient availability is a hallmark feature of pancreatic ductal adenocarcinoma (PDAC) 
cells (1–3), and PDAC cells are particularly well adapted to survive austere conditions as 
compared to other aggressive cancers (4, 5). In addition, PDAC cells are relatively resistant 
to conventional chemotherapy (5, 6). Because mathematical models implicate the harsh 
microenvironment as a principal driver of aggressive cancer biology (7), we reasoned that 
insights into PDAC molecular reprograming in response to metabolic stress could shed light 
on chemotherapy resistance mechanisms. For example, both low nutrient conditions and 
chemotherapy are potent inducers of reactive oxygen species (ROS; refs. 8, 9), suggesting 
that adaptive prosurvival reprogramming in response to oxidative stress caused by nutrient 
withdrawal, may also prime or prepare PDAC cells against additional oxidative stressors like 
chemotherapy.
HuR (ELAVL1) is an acute stress response and RNA binding protein that has been reported 
to have important regulatory functions under oxidative stress (10, 11). In fact, detailed x-ray 
crystallography reveals that activation of the protein, reflected in nuclear to cytoplasmic 
translocation, occurs only after homodimerization mediated by an oxidized disulfide bridge 
(12). These findings invite speculation that the protein may act as a redox sensor. We 
previously established a role for HuR as a regulator of chemotherapy resistance in PDAC 
cells (13), and more recently as a prosurvival protein in response to hypoxia (14) and 
glucose withdrawal (15). On the basis of this work, we hypothesized that PDAC cells 
enhance antioxidant defense under diverse metabolic stressors (like nutrient withdrawal and 
chemotherapy) by recruiting HuR.
Herein, we observe for the first time that nutrient deprivation alone (which is a ubiquitous 
physiologic stress in PDAC; refs. 1–3) results in chemotherapy resistance in pancreatic 
cancer, through the activation of an HuR-mediated prosurvival network. This finding has 
important implications for current standard of care, and could shed light on why PDAC cells 
are so refractory to conventional cytotoxic agents (16) compared to other cancer types (4). 
We present data that PDAC survival under low nutrient conditions, as well as chemotherapy, 
is attributable to rapid mobilization of an antioxidant defense program, and that the NADPH 
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generating enzyme, isocitrate dehydrogenase 1 (IDH1), is the critical regulatory target under 
HuR control for this purpose.
Materials and Methods
Cell lines and cell culture
MiaPaCa2, Panc-1, BxPC3, and HS-766T PDAC cell lines were obtained from the ATCC 
(2013). All cell lines were tested routinely and prior to all metabolomic analyses, for 
mycoplasma contamination and grown at 37°C and 5% CO2. Parental lines and their genetic 
modifications are summarized in Supplementary Table S1. Early passages (3–5) of these 
cultured cells were used for all the experiments. Under standard culture conditions, DMEM 
(containing 25 mmol/L glucose or 450 mg/dl, and 4 mmol/L glutamine or 36 mg/dl) was 
used. Media was supplemented with 10% FBS, 1% L-glutamine (200 mmol/L), and 1% 
penicillin/streptomycin (Invitrogen). In this study, 5 mmol/L glucose and 500 µmol/L 
glutamine were typically used to simulate nutrient withdrawal. Although the literature 
quotes these as normal levels in patient serum, they more accurately produce a relative 
nutrient withdrawal in cell line cultures chronically adapted to nutrient abundance. Lower 
doses may result in excessive toxicity and therefore can confound interpretation of biologic 
assays (15). Moreover, nutrient levels decline steadily over multiday experiments well into 
the subnormal range (15). For all in vitro assays, experiments were performed in triplicate.
MiaPaca2 cells with stable doxycycline inducible suppression of HuR were generated using 
lentiviral transduction of shRNAs using a Tet-pLKO-puro backbone plasmid (Addgene; 
21915), as described (17). CRISPR/Cas9-mediated knockout of HuR in MiaPaCa2 and 
HS-766T cells was accomplished using a guide RNA targeting HuR, fused with CRISPR/
Cas9 and GFP protein (18). Plasmids were designed and purchased from (Sigma-Aldrich) 
along with the CRISPR Universal Negative Control plasmid (CRISPR06-1EA). Stable cell 
line cultures with IDH1 overexpression were generated using MiaPaCa2 cells previously 
modified as CRISPR/Cas9 HuR knockouts. IDH1 transduction was performed in these cells 
using retroviral transduction of a pBABE-puro-WT.IDH1 plasmid, generously provided by 
Kun-Liang Guan (Moores Cancer Center, University of California, San Diego, CA). 
Scrambled pBABE-puro was used as a negative control plasmid (Addgene; 1764).
Drug sensitivity assays
Gemcitabine, oxaliplatin, and N-acetyl cysteine were purchased from Sigma-Aldrich. Drugs 
were dissolved in DMSO, PBS, and cell culture media, respectively. Cells were plated in 96-
well plates at 103 cells per well and assayed using Quant-it PicoGreen dsDNA Assay Kit 
(Invitrogen) at 5 days (13). To estimate cell death, cells were trypsinized at 24 hours and 
counted after Trypan blue staining (Invitrogen) with a Hausser bright-line hemocytometer 
(Fisher Scientific).
Small RNA interference, cDNA transfections
HuR overexpression and siRNA transfections were performed as previously described (13, 
15). Overexpression (OE) and empty vector (EV) plasmids were purchased from OriGene 
Technologies (pCMV6-XL5; SC116430). siRNA oligos were purchased from Life 
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Technologies (siIDH1, 7121; siCTRL, AM4635). The siRNA against HuR (referenced 
herein as si.HuR) was a customized oligo designed to minimize off-target effects (sequence 
CCAUUAAGGUGUCGUAUGCUCUU).
Western blot analysis, immunofluorescence, ribonucleoprotein immunoprecipitation, half-
life assays, and RNA quantitation
Protein detection and RNA quantitation (RT-qPCR) were performed using standard 
methodology, as previously described (13). When subcellular fractionation was performed 
for protein extraction, samples were prepared using the NE-PER Kit (Thermo Fisher 
Scientific). Membranes for immunoblotting were probed with antibodies against HuR (Santa 
Cruz Biotechnologies; 5261 clone 3A2), IDH1 (Abcam; ab 184615), GAPDH (Cell 
Signaling Technology; 5014), and α-Tubulin (Invitrogen; 32-2500). Actinomycin D (a 
transcription inhibitor) was used for half-life assays (ActD; 5 µg/mL; Fisher Scientific).
For immunofluorescence, cells were cultured at 5,000 cells per well on coverslips in 24-well 
plates. After appropriate treatments, cell were fixed with 3.7% paraformaldehyde for 10 
minutes, permeabilized with 0.1% Triton-X 100 for 30 minutes, blocked with 5% goat 
serum for 1 hour at room temperature, and incubated with primary antibody (γH2AX; 
Millipore; JBW301; 1:500, HuR; Santa Cruz Biotechnologies; 5261 clone 3A2; 1:200, 
IDH1; Abcam; ab 184615; 1:300) overnight at 4°C Alexa Fluor 488 F anti-mouse secondary 
antibody was applied to coverslips for 1 hour the following day, nuclei were stained with 4′,
6′-diamidino-2-phenylindole (DAPI) and mounted (ProLong Gold, Life Technologies) for 
analysis with a Zeiss LSM-510 Confocal Laser Microscope. After confocal acquisition, foci 
were quantified blindly using single plane images and plotted ± SEM (n = 30 foci counted).
Metabolomic profiling
For steady-state metabolomic analyses, cells were grown to ∼50% confluence in complete 
growth media on six-well plates in biological triplicates. The following day, complete media 
was exchanged with 25 or 5 mmol/L glucose media containing the [1,2-13C2]glucose tracer 
(Cambridge Isotope Labs), and cells were incubated for 24 hours prior to metabolite 
extraction. Metabolite fractions were extracted and analyzed by targeted gas 
chromatography-mass spectroscopy (GC-MS) via selected reaction monitoring (SRM), as 
previously described (19). Resulting mass isotopomer distributions were integrated and 
corrected for natural abundance using in-house algorithms.
Bioenergetics other metabolic assays
Measurements of mitochondrial function were undertaken using the Seahorse XF24 
Extracellular Flux Analyzer (Seahorse Bioscience) as detailed in the supplemental section. 
The NADP+/NADPH ratio (Abcam; ab65349), intracellular GSSG/GSH ratios (Abcam; 
ab138881), α-ketoglutarate (BioVision; K677-100), and ATP (Abcam; 83355) were 
performed per the manufacturer’s instructions. For ROS assays, cells were incubated with 5 
µmol/L 2′,7′-dichlorodihydrofluorescein diacetate (DCFDA; Invitrogen) and fluorescent 
DCF was measured per the manufacturer’s instructions. For the mitochondrial ROS levels, 
cells were incubated with 5 µmol/L MitoSOX Red mitochondrial superoxide indicator 
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(Invitrogen; M36008) and the fluorescence measured per the manufacturer’s instructions 
using the GloMax Explorer system (Promega). Values were normalized to total protein.
Xenograft studies
All experiments involving mice were approved by the Thomas Jefferson University 
Institutional Animal Care Regulations and Use Committee. Six-week-old, male, athymic 
nude mice (Nude-Foxn1nu) were purchased from Harlan Laboratories (6903M). MiaPaca2 
cells, or genetically modified variants of this cell line, were prepared in 100 µL solution 
comprised of 70% DPBS and 30% Matrigel. Suspensions of 5 × 106 cells were then injected 
subcutaneously into the left and right flanks of mice. Tumor volumes were measured three 
times per week using a caliper (volume = length × width2/2), along with body weights. 
Additional details are provided in supplemental experimental procedures.
Luciferase reporter assays
The full-length IDH1 3′UTR was subcloned into the psiCheck2 vector (Promega) at the 
XhoI and NotI restriction enzyme sites. A deletion series of the IDH1 3′UTR based on HuR 
binding predictions was generated as previously described (13). Renilla luciferase activity 
was normalized to firefly luciferase activity.
Immunohistochemistry
A tissue microarray (TMA) of resected PDAC and other periampullary cancer samples was 
prepared with formalin and embedded in paraffin, using tissues from previously consented 
patients undergoing treatment at Thomas Jefferson University Hospital. Standard 
immunolabeling techniques and IHC scoring were performed as described (20, 21) and 
detailed in the Supplemental section.
RNA sequencing
RNA seq was performed on an Illumina NextSeq 500 machine, and RNAs were interrogated 
from two different PDAC cell lines (MiaPaCa2 and HS-766T), both subjected to HuR 
deletion by CRISPR/Cas9 gene editing. Details of the techniques and bioinformatics are 
provided in the Supplementary section.
Clinical outcome data
All human subjects gave their written informed consent. For the clinical correlation analysis, 
we analyzed records from 724 consecutive patients with PDAC resected at Thomas Jefferson 
University Hospital between 2002 and 2014, after obtaining IRB approval. Clinical outcome 
analyses were separated into two related clinical cohorts, with details provided in the 
Supplementary section. In a cohort of 345 patients, HbA1C levels were available, along with 
pathologic descriptors (e.g., tumor size, lymph node status) of resected PDAC specimens. 
Patients were stratified by glycemic index (HbA1C or hemoglobin A1C) and correlation 
studies were performed to test for associations between HbA1C and pathologic features. For 
the survival analysis, 107 patients with resected PDAC who also underwent adjuvant 
chemotherapy were categorized into high glucose (HG, n = 86) and normal glucose (NG, n = 
21) groups using HbA1C when values were available or a prior clinical diagnosis of diabetes 
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as additional criteria of glycemic status. Recurrence data were available for these patients, 
and Cox multivariate hazard models were computed to estimate disease-free survival. 
Demographic details of the cohort are summarized (Supplementary Table S2).
Additional methodologic details for mouse studies, bioenergetics analyses, IDH1 mRNA 
analyses in patient specimens (from published datasets), IHC, RNA sequencing, and clinical 
outcome data are provided in the Supplementary Information.
Results
Low nutrient levels promote chemotherapy resistance in vitro
PDAC cells exhibited a 5- to 10-fold increased resistance to either gemcitabine (Fig. 1A) or 
oxaliplatin (Supplementary Fig. S1A) in vitro when exposed to low levels of glucose and 
glutamine over the course of the experiment. In the absence of chemotherapy however, 
PDAC cells had decreased cell survival under low glucose or glutamine conditions, 
compared to nutrient abundance (Supplementary Fig. S1B). As further evidence of nutrient 
withdrawal-associated chemoresistance, PDAC cells that were first precultured under low 
glucose conditions for 30 hours experienced less DNA damage with subsequent 
chemotherapy, as detected by a reduction in gamma H2AX foci formation, compared to cells 
cultured for the entire time under normal (supra-physiologic) culture conditions (Fig. 1B). 
As observed in prior studies (8, 9), nutrient withdrawal and chemotherapy proved to be 
potent inducers of ROS in PDAC cells (as measured by DCF fluorescence), with the greatest 
increase observed after simultaneous exposure of PDAC cells to both stressors 
(Supplementary Fig. S1C). However, when cells were again precultured initially for 30 
hours with low glucose or glutamine, subsequent gemcitabine treatment had an attenuated 
effect on ROS levels (Fig. 1C). Together, these data suggest that nutrient deprivation (a 
feature of the normal PDAC microenvironment) slows PDAC cell growth in the absence of 
treatment, but may initiate an adaptive pro-survival and antioxidant program that renders 
PDAC cells resistant to additional oxidative insults, such as chemotherapy.
Low nutrient levels promote chemotherapy resistance in vivo
We further evaluated whether nutrient deprivation contributes to chemotherapy resistance in 
vivo. Isolated manipulation of nutrient levels in the tumor alone (vs. the whole mouse) is a 
technical challenge. Therefore, we examined the impact of modulating peripheral glucose 
levels in mice on tumor growth, as prior studies have demonstrated that peripheral glucose 
levels vary directly with intratumoral glucose levels (22, 23). These studies reveal that small 
changes in serum glucose levels result in even larger changes in xenograft glucose levels 
(and in the same direction). Mice fed a high carbohydrate (HC) diet experienced more than a 
two-fold increase in peripheral glucose levels (median 173 mg/dL vs. 71 mg/dL by 4 weeks, 
P < 0.0001) compared to mice fed a ketogenic and calorie restricted diet (fed 75% of 
baseline calories, referred to herein as KCR75; Supplementary Fig. S2A). In the absence of 
chemotherapy treatment, hyperglycemic mice experienced a higher xenograft growth rate 
than hypoglycemic mice (top two curves, Fig. 2A). However, these proliferative tumors 
exposed to higher ambient glucose levels were much more responsive to gemcitabine 
(1,887.04 mm vs. 289.92 mm, 84% reduction, P = 0.0008) than slower growing tumors in 
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hypoglycemic mice (690.24 vs. 400.81, 41% reduction, P = 0.003; Fig. 2A and 
Supplementary Fig. S2B). These data suggest that in this animal model, like the in vitro 
model, nutrient withdrawal slows growth, yet induces a chemoresistant phenotype.
To further investigate the clinical relevance of this observation, we examined pathology and 
outcome data in a large cohort of patients who underwent surgery for pancreatic cancer. On 
the basis of the above preclinical studies, we hypothesized that high ambient glucose levels 
in patients may promote tumor growth in the absence of chemotherapy, but also render 
tumors more vulnerable to chemotherapy, compared to nutrient-deprived PDACs in 
normoglycemic patients. To test this hypothesis, patients were stratified by HbA1C levels, 
which is a chronic biomarker of glycemic status (24). As expected, tumors in hyperglycemic 
patients had worse pathologic features in their resected specimens. Specifically, patients 
with elevated HbA1C levels had larger tumors ssand increased regional lymph node spread 
observed at resection, prior to any exposure to chemotherapy (Supplementary Figs. S2C and 
S2D). Both of these pathologic features are validated prognostic predictors of poor outcome 
(25, 26), demonstrating that PDACs exposed to HG environments behave more aggressively, 
have increased growth, and even are more likely to metastasize (keeping with the trend 
observed in the mouse study). Despite this finding, in a subgroup of patients who later 
received gemcitabine adjuvant therapy, patients with HG levels (i.e., the more aggressive 
cancers) surprisingly experienced superior disease-free survival compared to patients with 
NG levels, even in an adjusted multivariate model that included important prognostic 
features (Fig. 2B and refs. 25, 26). The model in Supplementary Figure S2E summarizes the 
observations across these diverse PDAC systems (in vitro, in vivo, patients); whereas PDAC 
cells grow more slowly under nutrient withdrawal, harsh conditions (i.e., a low glucose 
environment) induce chemotherapy resistance.
Silencing HuR combined with nutrient withdrawal inhibits tumor growth in vivo
We pursued the regulatory mechanism behind PDAC adaptation to low nutrient conditions, 
both in the presence and absence of chemotherapy. Recent work by our group demonstrated 
a protective role for the RNA binding and regulatory protein, HuR, for PDAC cell survival 
under low glucose conditions (15). This prior work included in vitro experiments performed 
under glucose withdrawal, but did not further investigate the impact of HuR on PDAC cell 
viability after withdrawal of other nutrients, with chemotherapy treatment, or in an animal 
model (all addressed in this study). As a first step towards answering these questions, we 
used a previously generated doxycycline inducible shRNA PDAC xenograft system 
(MiaPaCa2.sh.HuR) to reversibly silence HuR with oral doxycycline (17). Cell culture 
validation of the system is provided in Supplementary Figure S3A. Again, mice fed a 
ketogenic and calorie-restricted diet had markedly lower peripheral glucose levels 
(Supplementary Fig. S3B). Mice fed the KCR diet had a median glucose level of 69 mg/dL 
at 4 weeks, as compared to 171 mg/dL in mice with HG levels (P < 0.0001). Decreased 
tumor growth was observed in mice with low peripheral glucose levels in the absence of 
doxycycline (HuR-proficient xenografts; Fig. 3A), but the combination of low glucose levels 
and HuR silencing (with doxycycline) had the greatest impact, essentially thwarting any 
additional xenograft growth beyond 4 weeks (Fig. 3A and Supplementary Fig. 3C). HuR 
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mRNA and protein silencing in the xenografts was confirmed by both qPCR and 
immunoblot, from xenograft lysates obtained after 50 days (Supplementary Fig. S3D).
Like glucose withdrawal, glutamine withdrawal activates HuR
The impact of glutamine withdrawal (as an alternative to glucose withdrawal) on HuR 
biology was assessed to determine if adaptive reprogramming by HuR was applicable to 
other nutrient sources, beyond glucose deprivation. Glutamine withdrawal indeed induced 
HuR translocation from the nucleus to the cytoplasm in MiaPaCa2 parental cells (similar to 
glucose withdrawal; ref. 15), as detected by both immunofluorescence (Supplementary Fig. 
S4A) and immunoblot of cytoplasmic lysates (Supplementary Fig. S4B). In both 
MiaPaCa2.si.HuR and Panc1. si.HuR cells, HuR silencing impaired cell viability with 
decreasing levels of glutamine in the absence of chemotherapy (PicoGreen assay, seven-fold 
decrease in the IC50; Supplementary Fig. S4C). In contrast, HuR overexpression 
(MiaPaCa2.HOE and Panc1.HOE) was protective under these conditions (8.65-fold increase 
in IC50; Supplementary Fig. S4C). These findings were further validated by a Trypan Blue 
assay, with a 15% to 30% increase in cell death by 72 hours (Supplementary Fig. S4D). 
Importantly, HuR also affected chemo-response under low nutrient conditions. HuR 
silencing not only prevented nutrient withdrawal-associated chemoresistance observed above 
in parental cells (a five-fold affect, see Fig. 1A), but rather sensitized MiaPaCa2.si.HuR cells 
to gemcitabine by an additional five-fold compared to MiaPaCa2.si.CTRL (Fig.3B and 
Supplementary Fig. S4E).
HuR minimizes the levels of ROS in PDAC cells
Through multiple independent assays, HuR expression reduced ROS levels under low 
glucose, whereas HuR silencing augmented ROS levels. For instance, compared to 
MiaPaCa2.si.CTRL cells, MiaPaCa2.si.HuR cells had a rise in the NADP+/NADPH ratio, 
GSSG/GSH ratio, DCF fluorescence, and mitochondrial ROS (Fig. 4A – D). Oxidative stress 
trended the highest when PDAC cells were simultaneously exposed to both glucose 
withdrawal and gemcitabine (Fig. 4C).
Conceptually, HuR could possibly mitigate ROS levels by either reducing ROS production 
or by enhancing ROS clearance. Because mitochondria are the dominant producers of ROS 
in cancer cells (27), we tested the former possibility first by examining the effect of HuR on 
diverse mitochondrial functions. Diminution of mitochondrial function would be one 
strategy for cancer cells to lower ROS production. Although glucose withdrawal increased 
oxygen consumption in parental MiaPaCa2 cells (Seahorse XF analysis; Supplementary Fig. 
S5A), the increase was effectively blocked by transient HuR silencing (Fig. 4E). In addition, 
HuR silencing minimized cellular ATP levels under low glucose conditions (Supplementary 
Fig. S5B). We traced the fate of 13C from [1, 2-13C2]glucose by GC-MS in HuR-knockout 
cells [Mia.HuR(−/−) vs. Mia.HuR(+/+)], and observed a mild attenuation of carbon flux in 
the TCA cycle under low glucose conditions in Mia.HuR (−/−), as evidenced by lower M2 
fractions of multiple relevant metabolites (Fig. 4F and Supplementary Figs. S5C). Because 
HuR generally augments mitochondrial activity according to these findings, increased HuR 
expression or activity is unlikely to attenuate mitochondrial ROS production. Instead, the 
data collectively point to enhanced ROS clearance (as opposed to diminished ROS 
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production) as the principal mechanism of HuR-mediated ROS control in glucose-deprived 
PDAC (as summarized in Supplementary Fig. S5D).
HuR impacts antioxidant defense by regulating IDH1
We performed unsupervised deep RNA sequencing in two different PDAC cell lines 
modified by CRISPR/Cas9 editing to delete HuR expression (MiaPaCa2 and HS-766T). 
RNA expression was compared in HuR(−/−) and HuR(+/+) cells (Supplementary Table S3 
lists the results for coding transcripts), with a particular focus on 40 established antioxidant 
enzymes (Supplementary Tables S4 and S5). A total of 15 enzymes were significantly 
dysregulated in at least one of the two HuR(−/−) cell lines compared to the HuR(+/+) lines, 
but only IDH1 (isocitrate dehydrogenase 1) was suppressed in both Mia.HuR(−/−) and 
HS.HuR(−/−) cells (Fig. 5A). Moreover, the magnitude of IDH1 suppression in HuR(−/−) 
cells compared to HuR(+/+) cells was even greater than the decrease in HuR expression (or 
ELAVL1, included in Fig. 5A as a reference). IDH1 is a cytosolic enzyme that catalyzes the 
interconversion of isocitrate and α-ketoglutarate, and couples this redox reaction to NADP+/
NADPH (Fig. 5B). Oxidative decarboxylation (rightward direction in Fig. 5B) produces 
NADPH. We validated the RNA seq findings through a separate HuR silencing experiment 
in MiaPaCa2 cells under low glucose conditions. Out of the eight different NADPH 
generating enzymes listed at the top of Supplementary Table S4, only IDH1 was markedly 
downregulated by HuR silencing (Supplementary Fig. S6A). The importance of IDH1 under 
acute glucose withdrawal, compared to these other NADPH generating enzymes, was further 
suggested by the observation that it was one of just two enzymes to increase in expression 
with this metabolic stress (Supplementary Fig. S6B). Downregulation of IDH1 was further 
confirmed in a separate in vivo experiment using the doxycycline-inducible sh.HuR system; 
IDH1 mRNA levels were indeed reduced in MiaPaCa2.sh.HuR cells when mice were fed 
DOX-supplemented chow for 43 days (Supplementary Fig. S6C). Next, an HuR-specific 
ribonucleoprotein immunoprecipitation (RNP-IP) assay was performed in MiaPaCa2 cells, 
providing evidence that HuR binds directly to the IDH1 mRNA transcript, similar to DCK, 
an established HuR target (ref. 20; Supplementary Fig. S6D, GLUT1 serves as a negative 
control; ref. 15). IDH1 mRNA and protein expression were virtually undetectable in both 
Mia. HuR(−/−) and HS.HuR(−/−) compared to the control cells (Fig. 5C and Supplementary 
Fig. S6E), proving that HuR is required for IDH1 expression in these models. As 
confirmation that HuR regulates IDH1, reintroduction of HuR into Mia.HuR(−/−) and 
HS.HuR(−/−) cells restored IDH1 expression (Supplementary Fig. S6F).
A computational analysis of a publically available HuR-crosslinking immunoprecipitation 
(CLiP) Seq dataset (28) identified five AREs in the 3′UTR of the IDH1 transcript as 
potential HuR binding sites (Supplementary Fig. S7A). We therefore subcloned the entire 
3′UTR containing these sequences into a luciferase reporter plasmid and measured the 
impact of HuR expression on reporter activity in MiaPaCa2 cells, as definitive proof of a 
regulatory interaction. Transient HuR silencing and overexpression impacted luciferase 
activity in an HuR-dependent manner, especially under low glucose conditions (Figs. 5D; 
Supplementary Fig. S7B). Subcloning of multiple deletion constructs derived from the full 
length IDH1 3′UTR further honed the critical regulatory sequence to the upstream 192 bp 
region, with functional contributions from each of the three predicted AREs within this 
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sequence (Supplementary Fig. S7C). Treatment of MiaPaCa2. si.HuR cells with actinomycin 
D (transcriptional inhibition) revealed a decrease in IDH1 mRNA stability, confirming that 
control of IDH1 transcript levels by HuR was post-transcriptional (Supplementary Fig. 
S7D).
HuR’s regulation of IDH1 enhances PDAC reductive power
We observed an increase in the α-ketoglutarate/citrate ratio in HuR-proficient Mia.HuR(+/+) 
cells upon glucose withdrawal (detected by GC-MS). However, the same increase was not 
observed in the Mia.HuR(−/−) cells (Supplementary Fig. S7E), providing biochemical 
evidence that the IDH reaction predominantly proceeds in the oxidative direction under low 
glucose to generate NADPH (rightward direction in Fig. 5B). Similarly, we observed a 
reduction in α-ketoglutarate levels in MiaPaCa2.si. HuR cells under glucose withdrawal (vs. 
MiaPaCa2.si.CTRL), using a separate redox-coupled colorimetric assay (Fig. 5E). These 
findings suggest that HuR’s regulation of IDH1 supports the generation of NADPH and 
reductive power under low glucose conditions.
HuR and IDH1 expression are associated in clinical specimens
The interaction between HuR and IDH1 was next assessed in patient clinical samples using a 
TMA derived from resected specimens of PDAC and other periampullary cancers. Both total 
and cytoplasmic HuR (the latter being the best marker of the activated protein; ref. 21) 
correlated with IDH1 protein expression by immunohistochemistry (Fig. 6A and B). In 
addition, we interrogated a publically reported gene expression microarray (29) for IDH1 
mRNA expression, and observed increased levels of the transcript in both primary and 
metastatic PDAC compared to normal tissue (Fig. 6C). These findings parallel previous 
observations by our group (20), and by others (30), which revealed that cytoplasmic HuR 
protein expression (i.e., the sub-cellular location where the protein most affects RNA 
stability of its bound mRNA targets) is increased in cancer tissues.
IDH1 can phenocopy HuR both in vitro and in vivo
We observed in vivo that CRISPR deletion of the HuR gene from PDAC cells [Mia.HuR(−/
−)] abrogated xenograft transplantation and uptake in the flanks of nude mice (18), 
underscoring the profound phenotypic impact of HuR expression on tumor growth in an 
animal model. In this study, stable reconstitution of IDH1 alone by retroviral transduction in 
these cells [Mia.HuR(−/−). IDH1OE] completely rescued engraftment potential (Fig. 6D).
Similar to MiaPaCa2.si.HuR in vitro (Fig. 4C), MiaPaCa2.si. IDH1 had increased ROS 
levels (DCF fluorescence) compared to MiaPaCa2.si.CTRL after nutrient withdrawal (either 
glucose or glutamine) and chemotherapy treatment (Supplementary Fig. S8A). Accordingly, 
IDH1 overexpression reduced ROS levels under these conditions (Supplementary Fig. S8B). 
IDH1 over-expression also enhanced NADPH levels under low glucose conditions in two 
PDAC cell lines (Supplementary Fig. S8C). Similar to MiaPaCa2.si.HuR above (Figs. 3B 
and Supplementary Fig. S4E), MiaPaCa2.si.IDH1 cells showed decreased cell survival with 
gemcitabine treatment (Supplementary Fig. S8D). The effect was particularly pronounced 
under glucose withdrawal. Moreover, increased DNA damage with gemcitabine was 
observed with MiaPaCa2.si.IDH1, whereas IDH1 overexpression (MiaPaCa2. IDH1OE) was 
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protective against DNA damage by gemcitabine (Supplementary Fig. S8E). The antioxidant, 
n-acetyl cysteine, was protective to both MiaPaCa2.si.IDH1 and MiaPaCa2.si.HuR cells 
after treatment with gemcitabine, under low glucose conditions (Supplementary Fig. S8F), 
further linking the HuR-IDH1 regulatory axis to antioxidant defense.
We performed IDH1 rescue experiments in an HuR-deficient background, by cotransfecting 
IDH1 cDNA plasmids with siHuR oligos, or by transfecting the plasmids into HuR-
knockout cells [Mia.HuR(−/−)]. In the presence of gemcitabine treatment, IDH1 
overexpression returned ROS levels, cell death, and DNA damage close to levels observed in 
untreated HuR-proficient cells (Fig. 7A–C and Supplementary Fig. S8G), to effectively 
restore chemo-resistance in these models.
Discussion
Pancreatic cancer lethality cannot be blamed solely on ineffective cancer screening and late 
cancer diagnosis. Rather, the evidence indicates that the disease is more aggressive than 
most other common cancers. For instance, survival with advanced disease is significantly 
worse than other cancers (31), and early lesions with microinvasion are more likely to spread 
and recur (32). Similarly, cytotoxic chemotherapy is less effective in PDAC (4, 5). The 
molecular changes that govern PDAC fitness in the face of severe stress like harsh conditions 
(1) or chemotherapy have not been fully elucidated. In recent years, there have been a 
growing number of studies addressing the question of how PDAC cells overcome the 
“desert”-like conditions present in the micro-environment. These studies were motivated by 
a presumption that metabolic dependencies in nutrient-deprived tumor tissue (1) may be less 
important or deprioritized in well perfused normal tissue. Thus, molecular insights into the 
metabolic dependencies of PDAC could uncover a natural therapeutic window. For example, 
Birsoy and colleagues observed in cancer cells that are well adapted to low glucose 
conditions, that mitochondrial function is enhanced in order to optimize ATP yield when 
nutrients are scarce (33). Commisso and colleagues, described macropinocytosis as an 
important mechanism for amino acid scavenging under nutrient deprived conditions in 
PDAC (34). Sousa and colleagues recently demonstrated that pancreatic stellate cells in the 
microenvironment provide alanine as an alternative carbon source under glucose-limiting 
conditions (35). In this study, we highlight two promising therapeutic targets (HuR and 
IDH1) with increased biologic importance for PDAC under physiologic and nutrient-
deprived conditions. Moreover, we propose that the HuR-IDH1 regulatory axis recruited in 
this context further protects at risk PDAC cells from additional oxidative insults, like 
chemotherapy, leading to a chemoresistant phenotype.
From a more broad perspective, we demonstrate using multiple different model systems (in 
vitro, in vivo, patients) that low nutrient conditions drives PDAC chemoresistance. For 
instance, we show in three different PDAC cell lines, that regardless of the reduced nutrient 
(glucose or glutamine), PDAC cells are substantially more refractory to cytotoxic therapy. 
Moreover, this pattern was not dependent on the mechanism of chemotherapy drug action 
(gemcitabine is an anti-metabolite and oxaliplatin is a DNA cross-linker). Further support 
for these findings was observed in both an animal model and actual patient data. Although 
the in vivo studies do not exactly parallel the cell culture experiments, in each model, more 
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austere conditions (withdrawal of glucose from the culture media, a low glucose mouse diet, 
or normoglycemia in patients) resulted in a diminished treatment response. Therefore, these 
findings may collectively offer insight into why current pharmacologic agents are largely 
ineffective under physiologic conditions. The data suggest that PDAC cells recruit a 
promiscuous prosurvival program under metabolic stress, which also confers resistance to 
conventional therapeutics.
In this work, we highlight antioxidant defense as one potential adaptive strategy used by 
PDAC cells to survive both harsh conditions and chemotherapeutic stress. More specifically, 
we demonstrate that HuR’s regulation of IDH1 is central to this task. IDH1 has been the 
subject of numerous studies in the cancer research field because of its high mutation 
frequency in many cancers (36). Of note, this genetic abnormality is exceptionally rare in 
PDAC, and has only recently been reported in a single case by our group (37). We theorize 
that the rarity of this mutation in PDAC is related to the deleterious effect that has been 
ascribed to haploinsufficiency of the wild type allele under very austere conditions (38). 
IDH1 mutations divert α-ketogluatrate to 2-hydroxyglutarate, and consume NADPH in the 
process. Although this chemical reaction is oncogenic in affected tumors, it can have 
devastating consequences on the reductive capacity of PDAC cells living in a highly 
oxidative environment. In fact, IDH1 mutant tumors tend to be less necrotic, less aggressive, 
and less chemoresistant (i.e., less “PDAC-like”) than their wild-type counterparts (39). It 
stands to reason that a lack of IDH1 mutations in PDAC provides indirect support for the 
importance of wild type IDH1 biology in PDAC.
Prior work has already demonstrated a prosurvival role for wild-type IDH1 in stressed 
cancer cells. For example, IDH1 activity promoted reductive carboxylation of α-
ketogluatrate under hypoxia as a compensatory lipogenic pathway in the context of impaired 
mitochondria (19). In addition, lower ROS levels attributed to wild type IDH expression 
enabled in vitro spheroid growth (a cell culture model where nutrient gradients exist; ref. 
40). In a separate study, IDH1-deficient mice were especially susceptible to oxidative liver 
damage with LPS administration (41). Because IDH1 is just one of eight NADPH generating 
enzymes, from four separate metabolic pathways (Supplementary Fig. S6A), its function on 
the surface may appear expendable. However, only IDH1 is regulated by the acute stress 
response and prosurvival protein, HuR. In fact, stable IDH1 overexpression restored 
xenograft uptake and growth in HuR-null PDAC cells, and IDH1 overexpression restored 
chemotherapy resistance in HuR-deficient PDAC cells exposed to nutrient withdrawal. Thus, 
PDAC cells may be particularly dependent on the HuR–IDH1 regulatory axis for adaptive 
survival under acute stress (as summarized in Fig. 7D), highlighting a potential metabolic 
vulnerability and therapeutic opportunity.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Low nutrient levels promote chemotherapy resistance in PDAC (in vitro model)
A, Survival of PDAC cell lines treated with the indicated doses of gemcitabine (GEM). IC50 
values are provided. Cell survival was calculated by measurement of dsDNA content using 
PicoGreen. B, γ-H2AX foci. MiaPaCa2 cells cultured for 48 hours and treated with 
gemcitabine for the final 18 hours. C, ROS levels in MiaPaCa2 cells by DCF fluorescence 
and under the indicated conditions for 48 hours. Cells were treated with gemcitabine (1 
µmol/L) for the final 18 hours. Error bars represent ± SEM of triplicate wells from a 
representative experiment. (N.S., nonsignificant; *, P < 0.05; **, P < 0.01; ***, P < 0.001). 
See also Supplementary Fig. S1.
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Figure 2. Low nutrient conditions promote chemotherapy resistance in PDAC (in vivo mouse and 
in patients)
A, Tumor growth curves of MiaPaCa2 PDAC xenografts in mice fed an HC or a ketogenic 
and calorie restricted diet (75% of the average caloric intake, KCR75). Each data point 
represents the mean ± SEM (n= 5 per group). *, P < 0.05; **, P < 0.01; ***, P < 0.001. B, 
Cox multivariate disease-free survival in patients receiving gemcitabine after resection for 
PDAC. See also Supplementary Fig. S2. GEM, gemcitabine.
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Figure 3. HuR protects PDAC cells against nutrient withdrawal and chemotherapy
A, Tumor growth curves of MiaPaCa2 PDAC xenografts containing a doxycycline (DOX)-
inducible shRNA construct against HuR (MiaPaCa2.sh.HuR). Mice were fed an HC diet, a 
ketogenic diet with 75% caloric intake (KCR75), or a ketogenic diet with 50% caloric intake 
(KCR50). Each data point represents the mean ± SEM (n= 8 per group). B, PicoGreen cell 
survival and drug sensitivity assays in MiaPaCa2 cells treated with gemcitabine (GEM). See 
also Supplementary Figs. S3 and S4.
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Figure 4. HuR minimizes ROS levels, while enhancing mitochondrial function
A, NADP+/NADPH ratio in MiaPaCa2 cells cultured under the indicated conditions for 24 
hours. B, GSSG/GSH ratio in MiaPaCa2 cells under the same conditions. C, ROS levels, 
detected by DCF fluorescence in MiaPaCa2 cells cultured in 5 mmol/L glucose media for 24 
hours, and gemcitabine (GEM; 1 µmol/L) as indicated. D, Mitochondrial-specific ROS were 
analyzed using MitoSOX in MiaPaCa2 cells cultured in 5 mmol/L glucose media for 24 
hours, and gemcitabine (1 µmol/L) as indicated. E, Oxygen consumption rates (OCR) in 
MiaPaCa2 cells, cultured in 5 mmol/L glucose for 24 hours. F, Quantitative 13C-isotope 
tracer labeling of TCA cycle intermediates (or surrogate metabolites, e.g., Asp) in MiaPaca2 
cells that were modified by CRISPR/Cas9 against HuR(−/−), or isogenic controls (+/+). 
Cells were cultured in 5 mmol/L glucose for 24 hours in the presence of [1,2-13C6]glucose. 
Each data point represents the mean ± SEM of three independent experiments. *, P < 0.05; 
**, P < 0.01; ***, P < 0.001. See also Supplementary Fig. S5.
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Figure 5. HuR regulates IDH1 expression in PDAC
A, RNA sequencing was performed in two PDAC cell lines (HS-766T and MiaPaCa2) 
modulated by CRISPR/Cas9 against HuR. The heatmap displays transcripts encoding 
antioxidant enzymes (out of 40 directly involved in ROS detoxification), with significant 
changes in HuR(−/−) cells as compared with the HuR(+/+) control cells. HuR (ELAVL1, the 
CRISPR deletion target) is included in the table as reference. B, Schematic of the reversible 
IDH1 catalytic reaction. NADPH is produced by oxidative decarboxylation. C, HuR and 
IDH1 mRNA levels in MiaPaca2 CRISPR HuR(+/+) or HuR(−/−) cells; immunoblot 
analysis of IDH1 and HuR protein in the same cells. D, MiaPaCa2 cells were cotransfected 
with siRNAs and luciferase reporter constructs (luciferase control or fused with IDH1 3′ 
UTR). Cells were cultured as indicated for 24 hours. E, αKG levels in MiaPaCa2 cells 
cultured under the indicated conditions for 24 hours. Error bars, ± SEM of triplicate wells 
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from a representative experiment. *, P < 0.05; **, P < 0.01; ***, P < 0.001. See also 
Supplementary Figs. S6 and S7.
Zarei et al. Page 21
Cancer Res. Author manuscript; available in PMC 2018 April 27.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 6. HuR is associated with IDH1 expression in clinical PDAC samples
A, Immunohistochemistry of HuR and IDH1 in formalin-fixed, paraffin-embedded PDAC 
tumors. The inset and arrow indicate cytoplasmic HuR expression. B, Tabulation and 
graphing of IHC scores from the TMA dataset shows cytoplasmic and total HuR IHC scores 
to be associated with IDH1 scores. Spearman correlation test yielded a significant 
correlation between the scores (P = 0.33, P < 0.01). Error bars display 95% confidence 
interval. C, IDH1 mRNA expression levels in normal pancreatic tissue, primary PDAC, and 
metastatic PDAC. For each boxplot, median expression value, and first and third quartiles 
are indicated. ***, P < 0.005; ****, P < 0.0000001. D, Representative images of 
subcutaneous MiaPaca2 xenografts (day 48) along with tumor growth curves. Each data 
point represents the mean ± SEM (n= 8 per group; ****, P < 0.0001). See also 
Supplementary Fig. S8.
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Figure 7. IDH1 rescues HuR-deficient PDAC cells from metabolic stress
A, ROS levels in MiaPaCa2 as measured by DCF fluorescence. The indicated culture 
conditions lasted 48 hours, with gemcitabine (GEM; 1 µmol/L) treatment for the final 18 
hours, as indicated. Cotransfections with siRNAs and overexpression plasmids were 
performed as indicated and repeated for B and C. B, PicoGreen cell survival and drug 
sensitivity assays in MiaPaCa2 cells. C, γ-H2AX foci in MiaPaCa2 cells. Culture and 
treatments paralleled the experiment in A. D, A schematic model of how HuR’s regulation 
of IDH1 promotes survival under nutrient withdrawal and chemotherapy treatment by 
enhancing reductive power and antioxidant defense. Error bars, ± SEM of triplicate wells 
from a representative experiment (N.S., nonsignificant; **, P < 0.01; ***, P < 0.001). See 
also Supplementary Fig. S8.
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